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Key Points 
 The use of ZOL is better than CLO in the improvement of SREs and survival in 
symptomatic myeloma patients at diagnosis. 
 Response category posttransplant may influence the impact of bisphosphonate therapy. 
Abstract 
Significant benefits for zoledronic acid (ZOL) over clodronate acid (CLO) were seen in the Medical 
Research Council Myeloma IX randomized trial. ZOL significantly reduced skeletal-related events 
(SREs), and improved progression-free survival and overall survival (OS), making it the 
bisphosphonate of choice for newly diagnosed myeloma patients. In this analysis of Myeloma IX 
data, we have investigated the impact of response on bone disease in 1111 transplant-eligible 
patients. At posttransplant day 100, complete response (CR) was seen in 48% of patients, very good 
partial response (VGPR) in 20%, and partial response (PR) in 23%. For patients in VGPR or less, 
ZOL was superior to CLO in reducing SREs (P = .048), whereas for patients in CR, both agents 
were equivalent (P = .83). For OS, ZOL was associated with a significant benefit in patients in PR 
(P = .0091). No difference in OS was seen with patients in CR (P = .91) or VGPR (P = .74). These 
findings indicate that response category posttransplant may influence the impact of bisphosphonate 
therapy. This trial was registered as #ISRCTN68454111 at www.isrctn.org. 
Introduction 
Multiple myeloma (MM) is characterized by an uncontrolled proliferation of clonal plasma cells in 
the bone marrow.
1
 A typical feature at presentation is the presence of osteolytic bone lesions in 
approximately 70% of patients, resulting in an increased risk of skeletal-related events (SREs).
2
 
Mechanistically, it is thought that MM plasma cells and bone marrow stromal cells secrete factors 
that stimulate osteoclast-mediated osteolysis, and inhibit osteoblast-mediated bone repair, resulting 
in unbalanced bone remodeling, leading to bone destruction.
3
 Furthermore, this cytokine 
dysregulation seems to be acting in a prosurvival fashion for the MM clone. Breaking this loop by 
therapy could affect survival.
4
 
Bisphosphonates are currently the standard approach for the management of bone disease in MM.
5,6
 
These pyrophosphate analogs have high bone affinity that inhibits osteoclastic activity, and 
additionally blocks growth factor release from the bone matrix, impairing MM growth.
7
 Preclinical 
and clinical evidence has suggested that zoledronic acid (ZOL) is superior to prior generations of 
such drugs.
8,9
 The Medical Research Council (MRC) Myeloma IX trial compared an intravenous 
amino-bisphosphonate (ZOL) with the oral first generation bisphosphonate clodronic acid (CLO) in 
newly diagnosed MM (NDMM), showing a significant benefit on SREs, progression-free survival 
and overall survival (OS) for ZOL.
10⇓-12 
Based on these results, ZOL is recommended as the bisphosphonate of choice in symptomatic 
NDMM.
13
 There remains considerable interest in how the achievement of deep responses impact on 
bone disease and the necessity for ongoing bisphosphonate treatment. Current guidelines lack 
evidence to support firm decisions regarding the optimal duration of bisphosphonates and the 
frequency of its dosing for patients achieving a complete response (CR) after effective induction 
treatments.
5,13
 To be able to fully understand the impact of response on bone disease and how this 
influences bisphosphonate treatment, we have performed a retrospective analysis of the Myeloma 
IX trial data, focusing on patients on the intensive pathway who were eligible for autologous stem 
cell transplantation (ASCT). This pathway is informative because of the high number of CRs 
achieved, providing insights into bone disease in patients in deep response. 
Study design 
In the MRC Myeloma IX trial, NDMM patients aged ≥18 years were enrolled. Full details of the 
trial have been previously reported.
10⇓-12,14 The protocol was approved by the relevant institutional 
review boards and ethics committees and this study was conducted in accordance with the 
Declaration of Helsinki. Patients were randomized to receive induction chemotherapy with either 
cyclophosphamide-vincristine-doxorubicin-dexamethasone or oral cyclophosphamide-thalidomide-
dexamethasone (CTD) and selected for ASCT (melphalan 200 mg/m
2
) based on their ability to 
tolerate it. In addition, at initial randomization, patients were allocated to receive ZOL (4 mg/every 
3-4 weeks) or CLO (1600 mg/d), until progression. The presence of bone lesions on axial skeletal 
survey at baseline were defined as myeloma bone disease. SREs were defined as vertebral fractures, 
other fractures, spinal cord compression, need for radiation or surgery for bone lesions and new 
osteolysis, and were recorded every 3 months, until progression. CR was defined as negative 
immunofixation of serum and urine (100% monoclonal-protein reduction), and very good partial 
response (VGPR) as at least 95% reduction in paraprotein levels assessed by central laboratory 
analysis in Birmingham. Analyses were based on the intention-to-treat population. Responses post-
transplant were analyzed on the population that received ASCT and were treated per-protocol. Time 
to first SRE was assessed by use of a cumulative incidence function, and compared with Gray’s 
test.
15,16
 Relapse/death was used as a competing risk event. P values for the Kaplan-Meier analyses 
were calculated using the log-rank test.
17
 
Results and discussion 
Between May 2003 and November 2007, 1114 patients were enrolled in the intensive pathway; 
1111 patients were evaluable, of whom 555 were randomly assigned to ZOL and 556 to CLO. 
Overall, 556 patients were randomized to receive cyclophosphamide-vincristine-doxorubicin-
dexamethasone and 555 to oral cyclophosphamide-thalidomide-dexamethasone. After induction, 
749 patients went on to ASCT. Baseline characteristics of the patients were already reported and 
were well balanced between the bisphosphonate groups.
10
 At baseline, 73% of patients had bone 
disease. Median follow-up was 5.71 years and 5.54 years for patients in the ZOL and CLO groups, 
respectively. 
ASCT is an important component of therapy increasing response rates, and, in this study, the CR 
rate improved from 13% to 48% after ASCT. These high-quality responses translated into extended 
progression-free survival and potentially into OS.
18,19
 After ASCT, immunofixation negative CR 
was seen in 359 (48%) patients, VGPR in 150 (20%), and partial response in 171 (23%). CR was 
defined as negative serum/urine immunofixation and less than 5% plasma cells in the bone marrow, 
and was confirmed in 326 patients. 
Overall, 350 (31.5%) patients had an SRE before progression, or as the first event of progression. 
Fewer patients assigned to ZOL had an SRE compared with CLO (155 vs 202 patients; P = .003), 
and ZOL significantly reduced the risk for first SRE (P = .02). 
Looking at the differential impact of ZOL vs CLO on SRE risk, dependent on response status, we 
found that in patients with VGPR or less after ASCT, there was a significantly reduced risk of SREs 
associated with ZOL (P = .048). In contrast, in patients who achieved CR, no difference in the risk 
of SREs was observed (P = .83) (Figure 1). 
 
Figure 1. Cumulative incidence for first SRE by bisphosphonate (ZOL vs CLO). (A) Patients 
who achieved a VGPR or less posttransplant (P = .048); PR (hazard ratio 0.74 [HR]; 95% 
confidence interval [CI], 0.52-1.05); VGPR (HR, 0.87; 95% CI, 0.60-1.27). (B) Patients who 
achieved a CR posttransplant (HR, 1.05, 95% CI, 0.82-1.35; P = .83). 
We have observed that patients with bone disease at baseline had a significantly shorter OS 
compared with patients without bone disease (median 63.7 vs 70.9 months; P = .047). Looking at 
the impact of bisphosphonate type, ZOL was associated with a significantly increased survival vs 
CLO in these patients with bone disease at baseline (median 69.8 vs 58.8 months; P = .047). 
Similarly, the survival of patients treated with ZOL was significantly superior to CLO when a PR 
was achieved (median not reached vs 65.2 months; P = .009). However, in patients achieving a 
VGPR or CR, no difference in survival was observed (VGPR median 88 months vs not reached [P 
= .74]; CR 85.3 months vs not reached [P = .91]) (Figure 2). 
 
 
Figure 2. Overall survival for patients randomized to ZOL vs COL. (A) Patients who achieved 
partial response posttransplant (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.32-0.86; P 
= .0091). (B) Patients who achieved VGPR posttransplant (HR, 0.91; 95% CI, 0.54-1.54; P = .74). 
(C) Patients who achieved CR posttransplant (HR, 0.98; 95% CI, 0.70-1.36; P = .91). 
In addition, we found that in patients who achieved a CR, the incidence of SREs was not 
significantly different dependent on the bisphosphonate type. These results support the notion that 
when the MM clone is reduced to a minimum, the use of the more potent bisphosphonate has no 
greater impact on SREs or OS. In contrast, a clear benefit is observed in patients achieving VGPR 
or less after ASCT with the use of ZOL, suggesting that there is a substantial and ongoing bone 
resorption that can be significantly impacted by the use of ZOL. 
In NDMM treated with ASCT, ZOL remains the mainstay of treatment at presentation, irrespective 
of the bone disease status. In patients who fail to achieve a CR after ASCT, the use of ZOL 
significantly reduces the rate of SREs and improves survival, as compared with CLO. In contrast, in 
patients achieving a CR, this enhanced impact on SRE rate and survival was not seen. However, the 
available data do not provide definitive evidence that ZOL therapy can be discontinued without 
detriment in such patients. If decisions are taken to temporarily discontinue bisphosphonate therapy, 
we would stress that close monitoring and the early reintroduction of ZOL in the event of clinical 
suspicion of progression, would be necessary. Although there are some limitations with the current 
study, such as the retrospective non preplanned nature of the analysis, this is the only study that has 
evaluated the impact of response on bisphosphonate therapy in myeloma, and supports the 
continued use of ZOL in MM from its early phases until disease progression, or maybe, in some 
instances, until the achievement of complete response. 
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